News 26 mar 2024 Top Stories from Western Switzerland (March 2024) From innovative approaches in cardiac care and sustainable plastics to enhancing spinal cord injury therapies and advancing virtual power plants,...
Actualités 19 out 2023 Nouveaux fonds pour le traitement de régénération tissulaire de Mimix Biotherapeutics La société biennoise Mimix Biotherapeutics a annoncé la clôture d’un important tour d’investissement, auquel ont participé des investisseurs euro...
News 19 out 2023 Mimix Biotherapeutics’ breakthrough tissue regeneration treatment receives strategic investment Biel-based Mimix Biotherapeutics announced the closure of a significant investment round, drawing participation from both European and Asian inve...
Actualités 15 nov 2023 La technologie d’Aktiia fait progresser la recherche cardiovasculaire mondiale La start-up neuchâteloise Aktiia, pionnière de la surveillance de la pression artérielle sans brassard, s’est lancée dans une étude inédite en co...
S-GE Event Tomorrow's Health: Meet the Experts on Patient Data, Empowerment & Blockchain 17 jun 2021 17 jun 2021 Suíça
Actualités 13 fev 2023 L’Hôpital de La Tour va créer un campus de la santé à Genève L’établissement privé de soins de santé Hôpital de la Tour a conclu un accord de CHF 750 millions pour créer un grand projet de campus de santé a...
Spotlight 15 jun 2023 Access to Ecosystem Switzerland is a global leader in biotech, medtech and pharma. Find out what makes the Swiss life science industry unique and how your life scien...
News 23 nov 2022 Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million Women's and reproductive health specialist ObsEva has announced the sale of its license for ebopiprant to California-based biotech company Xoma f...
News 26 mai 2023 UCB: "It's difficult to beat Swiss quality - even the Chinese admit as much." UCB UCB is a global biopharmaceutical company based in Belgium. Since 1996, it has invested more than 600 million Swiss francs in a state-of-the-art ...
Success stories 09 jun 2022 La Svizzera offre condizioni interessanti e stabili per le aziende internazionali Merck Il leader scientifico e tecnologico Merck è presente in Svizzera da quasi un secolo. Oggi ha otto sedi, tra cui cinque impianti di produzione, e ...
S-GE イベント オンラインセミナー 「スイスと欧州から実現させるサーキュラーエコノミー」 / Circular Economy Realization for Japanese Companies through the Performance of Switzerland and Europe
Actualités 06 out 2020 SOPHiA GENETICS lève 110 millions de dollars Leader mondial de la médecine basée sur les données, SOPHiA GENETICS a conclu un tour de financement de 110 millions de dollars pour entrer dans ...
Actualités 26 abr 2021 Année record pour l’industrie biotechnologique de Suisse occidentale Les entreprises de biotechnologie basées en Suisse ont connu des investissements records au cours de l’année pandémique 2020. La région de Suisse...
News 06 out 2020 SOPHiA GENETICS raises $110 million Global leader in data-driven medicine SOPHiA GENETICS has closed a $110 million financing round to enter the next stage of its expansion, with a ...